Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial.

ABSTRACT: Background: An in silico screen was performed to identify FDA approved drugs that inhibit SARS-CoV-2 main protease (M^pro), followed by in vitro viral replication assays, and in vivo pharmacokinetic studies in mice. These studies identified atovaquone as a promising candidate for inhibiting viral replication. Methods: A 2-center, randomized, double-blind, placebo-controlled trial was performed among patients hospitalized with COVID-19 infection. Enrolled patients were randomized 2:1 to atovaquone 1500 mg BID versus matched placebo. Patients received standard of care treatment including remdesivir, dexamethasone, or convalescent plasma as deemed necessary by the treating team. Saliva was collected at baseline and twice per day for up to 10

SUBMITTER: Jain MK 

PROVIDER: S-EPMC9561237 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature